The Center For
This presentation is the property of its rightful owner.
Sponsored Links
1 / 34

ging PowerPoint PPT Presentation


  • 145 Views
  • Uploaded on
  • Presentation posted in: General

The Center For. C. ognitive. A. ging. M. &. emory. Clinical Translational Research Program. External Advisory Board Meeting June 19,2013. Mission:

Download Presentation

ging

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Ging

The Center For

C

ognitive

A

ging

M

&

emory

Clinical Translational Research Program

External Advisory Board Meeting

June 19,2013


Ging

Mission:

To conduct cutting-edge interdisciplinary clinical neuroscience and translational research, on age-associated cognitive, behavioral and emotional functioning, factors that contribute to impairments and functional decline, and future avenues for intervention.

Primary Objective:

translate basic science discoveries into clinical applications in order to slow, avert or restore age-related cognitive decline and memory loss.


Healthy vs pathological c ognitive a ging

Healthy vs. Pathological Cognitive Aging

  • What are the characteristics of “normal” cognitive aging?

  • How does it differ from pathological cognitive decline?

  • Do all cognitive functions eventually decline?

  • Why are some functions spared from age-associated decline?

  • Do certain cognitive function improve as people age?

  • What occurs as people reach very advanced age?

  • What is the trajectory of cognitive changes in the very old?

  • Are these changes linked to specific brain changes?


The aging brain unresolved questions

The Aging Brain: Unresolved Questions

  • What distinguishes normal from pathological brain aging as people reach advanced age?

  • To what extent is AD pathophysiology involved in cognitive decline with advanced age?

  • What are the contribution of other systemic metabolic and vascular factors?

Continued…..


Ging

  • Is age-associated cognitive decline bound to occur due to apoptosis or other epigenetic mechanisms even in the absence of AD or vascular and metabolic disturbances?

  • Are certain structural and functional brain changes avoidable if other risk factors are not present?

  • What biomarkers will be most useful in identifying risk factors and predicting change?

  • To what extent are these factors modifiable?


Neuroimaging as a biomarker

Neuroimaging as a Biomarker

  • How sensitive are structural and functional neuroimaging measures to these changes?

  • Do structural and functional MRI provide useful measures for predicting late-life cognitive change?

  • Which measures are the best predictive biomarkers?

  • To what extent do vascular and metabolic factors contribute to these changes?

  • Can cerebral blood flow and metabolic neuroimaging be useful in assessing these factors and predicting subsequent decline?

  • Can neuroimaging provide a s , along with structural and functional MRI, useful in assessing modifiable risk factors?


So what is needed

So What is Needed?

  • Normative cognitive, neuroimaging, and biological data from people who have reached advanced

  • Longitudinal measures over two time points (initially) to enable examination of rates of change by domains

  • Cognitive data sensitive to individual cognitive domains and change in the very old

  • Multimodal neuroimaging measures to characterize changes in brain structure and function, and cerebral hemodynamic and metabolic health.

Continued….


Ging

  • These measures should be obtainable within a single session enabling co-registration of structural, functional and pathophysiological MRI indices.

  • Neuroimaging measures should be collected along with cognitive measures outside the scanner providing validation of the MBI cognitive battery

  • Biological samples, including blood, should be obtained at each visit enabling epigenetic and proteomic analyses relative to the neuroimaging and cognitive measures.


A paradigm shift is needed

A Paradigm Shift is Needed

  • Rather than starting from the perspective of neurodegenerative disease, we propose to initially focus on people who have successfully aged.

  • By this we mean that they have survived to reach relatively advanced age in relatively good physical health, without significant cognitive or functional problems.

  • This will require being quite selective in our recruitment -necessitating the involvement of the four MBI programs.


Cam ctrp scope

CAM-CTRP SCOPE

  • Normal Memory and Cognitive Aging

  • Advanced age (> 70 years)

  • People with and without medical co-morbidities

  • Cognitive aging studies grounded in basic research

  • Broad range of cognitive functions besides memory (e.g. semantics, social cognition, decision making, creativity, etc.)

  • Neuroimaging and other neuroscientific methods

  • Clinical translation and interventions


Relationship to uf institutes

Relationship to UF Institutes

Dr. R. Cohen

Dr. M. Pahor

Dr. T. Ashizawa

Dr. D. Nelson


Cam ctrp faculty

CAM-CTRP Faculty

Ronald A. Cohen, Ph.D.

Natalie Ebner, Ph.D.

John Williamson, Ph.D.

Adam Woods, Ph.D.

Recruitment

Simon Davis, Ph.D.


Ging

CAM-CTRP Core Leaders

Marco Pahor, M.D.

Lauren Crump, M.P.H.

Steve Anton, Ph.D.

Christiaan Leeuwenburgh, Ph.D.

Christy S. Carter, Ph.D.

Michael Marsiske, Ph.D.

Hani Doss, Ph.D.

Todd Manini,Ph.D.

Song Lai, Ph.D.

Adam Woods, Ph.D.


Cam ctrp affiliate faculty

CAM-CTRP Affiliate Faculty

  • T. Ashizawa, M.D.

  • Russell Bauer, Ph.D.

  • Jennifer Bizon, Ph.D.

  • Dawn Bowers, Ph.D.

  • Robert Cook, MD, Ph.D.

  • Ming-Zhao Ding, Ph.D.

  • Vonetta Dotson, Ph.D.

  • Natalie Ebner, Ph.D.

  • Adam Falchook, M.D.

  • Tom Foster, Ph.D.

  • Kenneth Heilman, M.D.

  • Christina McCrae Ph.D.

  • Steven Nadeau, M.D .

  • Michael Okun, M.D.

  • Cate Price, Ph.D.

  • Ranganatha Sitaram, Ph.D.


Fellows and students

Fellows and Students

  • Eric Porges, PhD (Univ. of Chicago) Post-doctoral fellow

  • Talia Seider, BSc (Univ. of Calif.) Graduate Student

  • Six doctoral dissertations


Ging

Where do we go from here?”Answering the need for studies of healthy cognitive aging


Initiatives

Initiatives:

  • Neurocognitive Task Development

  • Biomarker Development

    • Neuroimaging

    • Electrophysiological

    • Proteomic

    • Genomic

  • Translational Research

  • Clinical Trials

  • Assemble supporting Cores

  • Assemble Affiliate Faculty

  • Equip new Building


  • Neurocognitive approaches

    Neurocognitive Approaches:

    • Implementation of MBI battery and NIH Cognitive Toolbox (core CAM-CTRP cognitive assessment)

    • Trajectory of change analyses -CAM-CTRP

    • Social cognition – Ebner

    • Cognitive-affective assessment – Dodson

    • Attention – Cohen, Heilman, Williamson, Woods, Falchook,

    • Semantic network analysis – Cohen, Heilman, Nadeau

    • Creativity – Heilman


    Neuroimaging

    Neuroimaging

    • Setup of CAM-CTRP Neuroimaging Analysis Laboratory

    • Interface with new UF CTSI computing systems

    • Implementation of standard multimodal neuroimaging protocol for CAM-CTRP studies

    • MRI standardization across MBI institutes

    • Collection of neuroimaging data: LIFE cohort

    • Advance metabolic neuroimaging (MRS)

    • Plan NIA proposal for inter-institute project


    Neuroimaging assessment

    Neuroimaging Assessment

    • Scout + parameter setup =~ 3 min

    • SENSITIVITY Reference scan =~2.5 min

    • MPRAGE =~ 5 min x 2

    • FLAIR =~ 3 min

    • ASL =~ 5 min

    • Phase contrast =~ 2min +1.5 min locator

    • BOLD =~ 2 * 5 min resting state OR 18 min for Task +rest

    • DTI = ~ 10 min

    • MRS =~ 7 min for ~1 ROI

    • (phantoms acquired at beginning of each day)


    Laboratory biomarker i nitiatives

    Laboratory Biomarker Initiatives

    • Proteomics and metabolomics

      • (e.g., cytokines)

  • Genomics

    • genetic

    • epigenetic


  • Laboratory biomarker plan

    Laboratory Biomarker Plan

    • Blood sample collection on CAM-CTRP participants

    • CSF collection in a limited sample

    • Other tissues?

    • CTSI Bio specimen repository


    Translational research some examples

    Translational Research(some examples)

    • Inflammation – neuroimaging mouse models

    • Phosphorus and carbon MRS imaging methods

    • Induced pluripotent stem cell (iPSC) initiative

    • MBI initiatives: ARML translation efforts

    • Computational neuroscience: Neural networks

    • Combined electrophysiology-FMRI

    • Drug challenges methodologies

    • Combined studies of cognitive and physical function


    Clinical trials for cognitive aging

    Clinical Trials for Cognitive Aging

    • Pharmaceutical

      • Vitamin D

      • Methotrexate

      • Testosterone

      • Resveratrol

      • Oxytocin

      • Neuroprotective Agents

      • Cognitive Enhancers

      • Vascular Function Enhancers

      • Performance Enhancers

    • Behavioral – Lifestyle

      • The Active Brain

      • CHORES-XL

      • Bariatric Surgery Study

      • LIFE

      • LIFE-ES

      • LIFE-ARISE


    Ging

    • Cognitive Training

      • VITAL- Bowers/Marsiske

      • Vigorous Mind- Cohen

      • Neurofeedback- Sitaram


    Cam ctrp core protocol

    CAM-CTRP Core Protocol

    • Neurocognitive measures

    • Neuroimaging and physiological

    • Laboratory biomarkers (blood, tissue, CSF)

    • Genomic sequencing (Leonid Moroz)

    • CTSI Bio Specimen Repository


    The active brain cohort

    “The Active Brain” Cohort

    • An inter-institutional cohort consisting of successful agers

    • People who have reached advanced age (75 – 90 years)

    • No evidence of significant cognitive or functional decline

    • No history of major medical problems (CVD, Stroke, etc.)

    • Well controlled vascular and metabolic risk factors

    • We estimate that a sample size of 500 (125 per site) assessed twice will provide sufficient power for initial analyses of cognitive aging effects.


    Specific objectives year 2

    SPECIFIC OBJECTIVES: Year 2

    • Implement junior scholars program

    • Facilitate proteomic and genomic initiatives

    • Continue integration with ARML

    • MBI Inter-Institute Initiative

    • Continue current R01-P01 supported research

    • Resubmission of Bariatric Grant and two new submissions

    • Branding of CAM-CTRP

    • Faculty recruitment

    • Transition to new IOA building

    • Integration with Pepper cores

    • Recruit cognitive aging cohort: LIFE-ancillary study

    • Support current IOA studies

    • Initiate multimodal neuroimaging initiative

    • Initiate pilot study program


    Ioa cam brain wellness clinic

    IOA-CAM Brain Wellness Clinic

    • Multi-disciplinary program

    • Geriatrics, Neurology, Psychiatry, Neuropsychology, Social Work and other supportive services

    • Provide assessment for older adults with concerns about cognitive decline

    • Receive referrals from community, psychiatry and other sources

    • Triage to the AD, PD, and other UF clinical programs

    • Provide support and interventions

    • Clinical trials

    • Facilitated by arrival of Dr. Solberg to direct clinical geriatrics at UF


    Ging

    IOA- CAM INTERFACE

    Clinic

    Research

    Cohort Development

    Study Recruiting

    Sponsored Clinical Trials

    Integrated Clinical and Research Operation

    Center Branding


    Ging

    Questions ?


  • Login